GSK's Fair Value Estimate Edges Higher Amid Mixed Analyst Sentiment

GSK's fair value estimate has been raised to £18.83 from £18.73, with some analysts increasing price targets despite caution around the company's pipeline and execution. JPMorgan raised its target to 1,500 GBp from 1,400 GBp while staying cautious, while Barclays downgraded GSK to Underweight from Equal Weight, highlighting limited upcoming pipeline readouts and the new CEO's limited room to maneuver. Analysts see mixed signals, with some supporting the current valuation while others flag execution risk and limited upcoming readouts.